FDA Antibiotic Restrictions Highlighted In Impavido Review
Executive Summary
Advisory committee members, worried about adherence to miltefosine regimen outside the U.S., urge FDA to require directly observed therapy in labeling.
You may also be interested in...
Paladin’s Impavido Poised For Smooth Advisory Committee
FDA reviewers did not identify any major problems with the application for treatment of three types of leishmaniasis, but did say the product may face resistance problems as use expands.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.